Vyome Holdings, Inc. (HIND)
NASDAQ: HIND · Real-Time Price · USD
5.01
-0.08 (-1.57%)
At close: Dec 5, 2025, 4:00 PM EST
5.08
+0.07 (1.40%)
After-hours: Dec 5, 2025, 7:59 PM EST
Vyome Holdings Revenue
Vyome Holdings had revenue of $34.63K in the quarter ending September 30, 2025, a decrease of -59.03%. This brings the company's revenue in the last twelve months to $344.59K, up 30.09% year-over-year. In the year 2024, Vyome Holdings had annual revenue of $256.94K, down -38.23%.
Revenue (ttm)
$344.59K
Revenue Growth
+30.09%
P/S Ratio
10.03
Revenue / Employee
$19,144
Employees
18
Market Cap
28.28M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 256.94K | -159.00K | -38.23% |
| Dec 31, 2023 | 415.94K | 33.08K | 8.64% |
| Dec 31, 2022 | 382.87K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionHIND News
- 11 days ago - Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program - Business Wire
- 18 days ago - Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing - Business Wire
- 4 weeks ago - Biomarker Deals Accelerate: Strategic Alliances Reshape Life Sciences Innovation - GlobeNewsWire
- 4 weeks ago - Vyome Holdings Announces Results of Annual Shareholder Meeting - Business Wire
- 2 months ago - Vyome Holdings Acquires MIT AI Spinout Oculo Health - Business Wire
- 2 months ago - Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market Opportunity - Business Wire
- 3 months ago - Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies - Business Wire
- 3 months ago - Vyome Holdings Announces Positive Interim Data from Phase 2 Study of VT-1953 in Malignant Fungating Wounds (MFW) and Provides Update on MFW market opportunity - Business Wire